Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Opinion|Videos|November 1, 2024
Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies
Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.
Advertisement
- Dr Gadgeel: How do these data impact your treatment choice for your patients?
- What specific patient factors would influence your decision between treatment options? What concerns might prevent you from choosing lorlatinib as a first-line treatment?
Advertisement
Related to this article
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
3
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5